Alderley Park Ltd

The UK's largest bioscience campus: dedicated to helping shape the future of the world's health. Alderley Park offers exceptional bioscience facilities for R&D focused life science companies at every stage of their life-cycle, from start-up to global corporate. Its Mereside campus is part of Manchester Science Partnerships, one of the leading science and technology park operators in Europe. Offering 1m sq ft state-of-the-art chemistry, biology and pathology labs, dedicated incubator facilities and a range of shared scientific services, it’s the ideal place to support pioneering innovation. MSP’s unique partnership connections and support services can also open the doors to new regional and national networks and funding, providing opportunities that can transform businesses and help take them to the next level. The Park is home to national centres of excellence including the AMR Centre and Medicines Discovery Catapult, alongside a cluster of life science companies including Cancer Research UK, Concept Life Sciences and Evotec, to name a few.

 

Mrs Elaine Wilson
Business Development Manager 
Mr Keith Miller
Life Science Specialist 

High Force Research

Headquartered in Durham, UK, High Force Research are proud to remain a truly independent chemistry CRO and R&D partner. We have core expertise in chemical R&D, process optimisation & development, custom synthesis, scale-up and cGMP manufacture of small molecule API's and their intermediates for pre-clinical studies and Phase I/II clinical trials. We collaborate with discovery groups, start-ups and spin-offs from academia and industry in synthesising new materials for proof-of-concept studies and in process development on the route to market. High Force Research has established dual contribution, shared risk joint venture collaborations with universities and SME's. We invest expertise, time and facilities to jointly develop novel, small molecule NCE's and clinical candidates. 
Jennifer Wallis
Business Development Executive 

LSX Ltd

LSX is the world’s first invoice exchange built on the blockchain. Invoices bought from alternative finance marketplaces around the world will be traded on this secondary exchange. LSX allows trading in fiat and cryptocurrency, including bitcoins and ethers, and is due for public release in late 2018.

Organisation type
Matthew Pullan
Senior Vice President